Skip to content

Clinical study on the effect of remimazolam injection combined with propofol on hemodynamics in patients undergoing general anesthesia

Clinical study on evaluating the effect of remimazolam injection combined with propofol on patient hemodynamics during general anesthesia in the real world

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107139
Enrollment
Unknown
Registered
2025-08-05
Start date
2025-08-11
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypotension

Interventions

Propofol Group:According to the routine anesthesia plan of each center (traditional anesthetics such as propofol and etomidate can be used), anesthesia induction and maintenance should be carried out.
Remimazolam Group:Use 0.25 mg/kg of remimazolam for anesthesia induction. There are no specific restrictions on analgesics and muscle relaxants, and the administration time should be completed within
If the patients consciousness disappears, maintenance medication will be administered. The criteria for consciousness disappearance after administration are: Modified Alert Sedation Score (MOAA/S scor
If the MOAA/S score of the patient is = 2 or the eyelash reflex does not disappear 3 minutes after the first administration, remimazolam 0.05mg/kg should be given again as a remedy. If consciousness d
In addition, no other sedatives are used
Retrospective experimental group:None

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing elective surgery under total intravenous anesthesia; 2.Gender not limited, age between 18 and 65 years old; 3. Body mass index (BMI) 18.5-28kg/m2; 4.ASA classification is I-III level; 5. No previous history of anesthesia drug allergies 6. There are no significant abnormalities in the heart, liver, lungs, or coagulation function; 7.Expected surgical duration not exceeding 4 hours; 8. Patients who are not expected to enter the ICU after surgery; 9. Voluntary signing of informed consent form.

Exclusion criteria

Exclusion criteria: 1.Individuals with allergic reactions to the drugs in this study; 2.Individuals with severe heart and lung dysfunction, liver and kidney dysfunction; 3. Patients with mental system disorders (such as schizophrenia, depression, etc.) and cognitive impairment; 4.Patients who have experienced acute upper respiratory tract infections and persistent asthma attacks in the past two weeks; 5.Patients who are highly likely to experience difficult airways (such as severe snoring, pathological obesity patients); 6.Long term use of sedatives, hypnotics, or psychotropic drugs; Pregnant or lactating women; 7.The researcher determines that the subjects are not suitable to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Secondary

MeasureTime frame
MMSE score;Anesthesia awakening time;Time for extubation of tracheal tube;Duration of stay in the recovery room;

Countries

China

Contacts

Public ContactLin Yunan

The First Affiliated Hospital of Guangxi Medical University

Lyunan@sr.gxmu.edu.cn+86 137 6827 8751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026